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Murine AIDS (MAIDS) develops in susceptible mouse strains after infection with the LP-BM5 murine leukemia virus
complex that contains causative defective, and ecotropic helper, retroviruses. We previously demonstrated that the MAIDSresistant H-2 d strains BALB/cByJ and C57BL/KsJ generate MHC class I (K d) restricted virus-specific CD8 ⫹ cytolytic T
lymphocytes (CTLs) that lyse cells expressing either defective or ecotropic gag proteins. In contrast, the congenic BALB.B
and closely related C57BL/6J MAIDS-susceptible H-2 b strains were unable to serve as a source of gag-specific CTLs
(Schwarz and Green, 1994), suggesting that anti-gag CTLs might provide a basis for resistance to MAIDS. Although its
susceptibility to MAIDS was unknown, the (BALB/c ⫻ C57BL/6J) F 1 (CBY6F 1) strain could also produce H-2 d-, but not H-2 b-,
restricted, anti-gag CTLs (Schwarz and Green, 1994). Because of this correlation between anti-gag CTLs and resistance to
MAIDS, it was important to provide more direct evidence in support of CTL-mediated protection and to determine both the
fine specificity of CByB6F 1 anti-gag CTLs, in comparison with the resistant C57BL/Ks and BALB/c strains, and the
susceptibility of this F 1 strain to LP-BM5-induced MAIDS. We report here that no symptoms of MAIDS were observed in
CBY6F 1 (H-2 d⫻b) mice. For F 2 mice, in contrast to the high susceptibility of H-2 b/b mice, 77% of H-2 d/d and 81% of H-2 b/d F 2 mice
did not exhibit MAIDS after LP-BM5 infection. These results are in contrast to other published studies that concluded that
susceptibility, rather than resistance, is dominant in F 1 (resistant ⫻ susceptible or susceptible ⫻ resistant) mice. We also
show that CBY6F 1 anti-gag CTLs exhibit a fine specificity shared by the MAIDS-resistant BALB/c and C57BL/Ks strains, that
is, the immunodominant gag epitope, SYNTGRFPPL, encoded by an alternative open reading frame. Together with our direct
demonstration here that in vivo monoclonal antibody (mAb) depletion of CD8 ⫹ T cells converts genetically resistant mice to
MAIDS susceptibility, these data on the ability to mount anti-ORF2/SYNTGRFPPL, gag-specific CTL responses strongly
suggest that CTLs are a primary factor in determining MAIDS resistance. Accordingly, given the K d-restricted nature of the
CTLs, the main genetic determinant of resistance appeared to be the codominant expression of the resistant H-2 d haplotype.
Interestingly, however, 19% of H-2 d/b and 23% of the H-2 d/d F 2 mice had at least one clinical aspect of MAIDS, suggesting that
a non-MHC genetic determinant(s) can negatively influence T-cell protection and thus disease outcome © 2000 Academic Press
Key Words: cytolytic T lymphocytes; antigens; peptides; epitopes; antigen presentation; MAIDS; rodent; immunodeficiency
disease; mRNA; MHC.

pathogens that cause only minor infections in healthy
mice (Buller et al., 1987). Because some of these disease
features resemble those of humans infected with HIV,
this mouse model is referred to as murine AIDS (MAIDS).
Although three classes of murine retroviruses have
been isolated from the LP-BM5 mixture, neither the BM5
ecotropic (BM5) nor mink cell cytopathic focus-inducing
(MCF) replication-competent viruses, alone or in combination, are able to cause MAIDS (Aziz et al., 1989; Chattopadhyay et al., 1989). Rather, the BM5 and MCF viruses
serve as helper viruses for the transmission of a replication-defective virus, which is the proximal etiological
agent of MAIDS (Jolicoeur, 1991; Chattopadhyay et al.,
1989, 1991). Large deletions within the pol and env genes
of this defective virus result in the production of only a
modified gag protein (Huang and Jolicoeur, 1990). With
the exception of a continuous stretch of about 25 amino

INTRODUCTION
The LP-BM5 isolate of murine retroviruses induces a
profound and progressive immunodeficiency in certain
inbred strains of mice (Mosier et al., 1985; Aziz et al.,
1989; Jolicoeur, 1991; Morse et al., 1992). After infection,
there is an early hypergammaglobulinemia and a generalized enlargement of lymphoid organs, including the
spleen and lymph nodes, probably due to an inappropriate activation and resultant proliferation of both B and T
lymphocytes. Ultimately, T and B lymphocytes are rendered hyporesponsive to either antigenic or mitogenic
challenge. As a consequence, LP-BM5-infected, immunosuppressed mice die after exposure to environmental

1
To whom reprint requests should be addressed. Fax: (603) 6506223. E-mail: William.R.Green@Dartmouth.edu.

0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.

438

ANTI-GAG CTLs SPECIFIC FOR AN ALTERNATIVE ORF

acids (AA) in the COOH-terminus of p15 and 25 AA in the
N-terminus of p12, the gag polyprotein encoded by the
defective virus shares significant homology with other
murine retroviruses, including the BM5 ecotropic helper
virus.
We have previously demonstrated that MAIDS-resistant, BALB/cByJ (BALB/c) and C57BL/KsJ (C57BL/Ks)
(H-2 d) mice generate MHC class I-restricted gag-specific
CD8 ⫹ cytolytic T lymphocytes (CTLs), which lyse cells
expressing either defective (dG) or ecotropic (eG) gag
proteins, as encoded by recombinant Sindbis virus or
vaccinia (Vac) virus expression. In contrast to these
MAIDS-resistant strains, the congenic BALB.B (H-2 b) and
closely related C57BL/6J (H-2 b) MAIDS-susceptible
strains were unable to serve as a source of gag-specific
CTLs (Schwarz and Green, 1994), suggesting that antigag CTLs might play a key role in resistance to LP-BM5induced MAIDS. Furthermore, the (BALB/c ⫻ C57BL/6J)
F 1 hybrid (CBY6F 1) strain could also be stimulated to
produce a population of H-2 d-, but not H-2 b-, restricted,
anti-gag CTLs (Schwarz and Green, 1994). Using human
143B or murine MC57 (H-2 b) cells coinfected with dG- or
eG-Vac-expressing viruses and recombinant vaccinia viruses expressing different H-2 d class I molecules, it was
shown that the anti-gag CTLs recognized a viral
epitope(s) presented in the context of H-2K d (Schwarz
and Green, 1994). In addition, we subsequently demonstrated that the fine specificity of BALB/c-derived, antigag CTLs was accounted for by a uniquely produced
epitope encoded in an alternative translational open
reading frame (ORF). Relative to the primary ORF (ORF1)
that encodes the structural defective or ecotropic viral
gag protein, the CTLs were specific for a minimal peptide
determinant defined as the ORF2-generated SYNTGRFPPL epitope (Mayrand et al., 1998; Mayrand and Green,
1998).
The ability of the CBY6F 1 mice to generate gag-specific CTLs was of particular interest because previous
studies with several F 1 (MAIDS-resistant ⫻ MAIDS-susceptible or MAIDS-susceptible ⫻ MAIDS-resistant)
strains have led to the conclusion that susceptibility,
rather than resistance, is dominant (Makino et al., 1990;
Huang et al., 1992). By way of contrast, HammelinBourassa et al. (1989) demonstrated that F 1 progeny of
the susceptible, C57BL/6 ⫻ resistant, A/J strains were
more resistant than susceptible to LP-BM5 virus-induced
MAIDS, and Makino et al. (1991) reported that 55% of the
F 1 progeny of resistant, RIIIS ⫻ susceptible, B10.RIII
strains were MAIDS resistant. Taken together, these latter two studies suggest that in certain F 1 strains, MAIDS
resistance may be dominant over MAIDS susceptibility,
whereas the opposite may be true for other F 1 strains.
Because the CBY6F 1 mouse strain can generate gagspecific CD8 ⫹ CTL responses apparently similar to those
characterized in the MAIDS-resistant BALB/c and
C57BL/Ks strains and unlike the MAIDS-susceptible
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C57BL/6 and BALB.B strains, it was important to determine the susceptibility of this F 1 strain to LP-BM5-induced MAIDS. If anti-gag CTLs are critical for resistance,
it would be paradoxical if CBY6F 1 mice would possess a
MAIDS-susceptible phenotype, as suggested for the majority of the (resistant ⫻ susceptible) F 1 strains cited
above. If, indeed, CBY6 F 1 mice demonstrate susceptibility to LP-BM5-induced MAIDS, however, differences in
the fine specificity of the gag-specific CTLs generated in
the BALB/c and C57BL/Ks versus CBY6F 1 strains could
account for the resistance versus susceptibility among
these mouse strains. Alternatively, perhaps anti-gag
CTLs are not the prime factor in determining resistance.
To further investigate these issues, experiments were
conducted in the present study to address three issues:
(1) Is there direct evidence that CD8 ⫹ CTLs confer resistance to MAIDS? (2) Do gag-specific CTLs derived from
H-2 d mouse strains other than BALB/c (i.e., C57BL/Ks
and CBY6F 1) share the ORF2-derived, SYNTGRFPPL
specificity of the BALB/c-derived anti-gag CTLs? (3) Are
CBY6F 1 mice, like many other (resistant ⫻ susceptible)
F 1 strains, susceptible to LP-BM5-induced MAIDS?
RESULTS
In vivo depletion of CD8 ⫹ CTLs converts resistant
mice to susceptibility to LP-BM5 murine leukemia
virus-induced MAIDS
To directly assess the contribution of CD8 ⫹ CTLs to
MAIDS resistance, prototypical resistant adult BALB/
cByJ mice were depleted in vivo of CD8 ⫹ T cells, and a
portion of these were concurrently infected with LP-BM5
virus (as detailed in Materials and Methods). Postinfection, weekly injections of purified anti-CD8 ascites were
administered to ensure that CD8 depletion was maintained. Confirmation of chronic CD8 ⫹ T-cell depletion
throughout the experiment was achieved via weekly flow
cytometric analyses of splenocytes from a control group
of mice that received only anti-CD8 treatment: ⬎95%
CD8 ⫹ cells were eliminated, compared with naive age/
gender-matched untreated mice (data not shown). This
untreated mouse group was also subdivided into uninfected versus LP-BM5-infected control subsets. Six
weeks after LP-BM5 infection, the mice were sacrificed
and evaluated for several parameters indicative of
MAIDS: spleen hyperplasia, elevated serum IgG 2a and
IgM levels, and diminished mitogenic responses [ConA
and lipopolysaccharide (LPS)]. LP-BM5-infected C57BL/6
mice, included in parallel as positive controls for the
ability of the LP-BM5 virus preparation used in this experiment to induce MAIDS, demonstrated characteristically severe splenic hyperplasia, hypergammaglobulinemia, and inhibited mitogenic responses as a measure of
immunosuppression (data not shown).
As depicted in Fig. 1, anti-CD8 treatment converted
LP-BM5-infected BALB/cByJ-resistant mice to clear
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FIG. 1. Resistance to LP-BM5 virus-induced MAIDS requires CD8 ⫹ T cells. BALB/c adult mice were either untreated, infected with LP-BM5 virus,
chronically depleted of CD8 ⫹ T cells by in vivo mAb infusion, or both virus infected and depleted of CD8 ⫹ T cells (see Materials and Methods). At
6 weeks postinfection, the mice were sacrificed, and spleen weight was determined as an index of MAIDS susceptibility. Student’s t test-determined
P values of ⬍0.05 were accepted as statistically significant differences among treatment groups.

MAIDS susceptibility, based on these multiple disease
criteria. For example, splenic hyperplasia was obvious.
CD8-depleted and LP-BM5-infected mice exhibited an
average spleen weight of 1.53 ⫾ 0.12 g/100 g body weight
(BW) compared with naive mice or mice treated with
either only anti-CD8 (0.50 ⫾ 0.09 g/100 g BW; P ⫽ 0.001)
or only LP-BM5 virus (0.55 ⫾ 0.04 g/100 g BW; P ⫽ 0.001).
These results were corroborated by both serum IgG 2a
and IgM levels (data not shown). Specifically, anti-CD8treated/LP-BM5-infected mice were hypergammaglobulinemic with average serum IgG 2a levels of 558 g/ml
compared with either noninfected, anti-CD8-treated mice
(209 g/ml; P ⫽ 0.006) or nondepleted, LP-BM5-infected
mice (245 g/ml; P ⫽ 0.013). Additionally, anti-CD8-treated/LP-BM5-infected mice had average serum IgM levels
of 511 ⫾ 26 g/ml compared with noninfected, anti-CD8treated mice (146 ⫾ 27 g/ml; P ⫽ 0.001) or nondepleted,
LP-BM5-infected mice (171 ⫾ 9.3 g/ml; P ⫽ 0.001).
Similarly indicative of MAIDS were the immunodeficiency parameters examined. Thus the ability of antiCD8-treated/LP-BM5-infected mice to generate T-cell
and B-cell mitogen responses was substantially diminished compared with both uninfected anti-CD8-treated
mice (P ⫽ 0.001 for ConA and P ⫽ 0.003 for LPS) and
nondepleted, LP-BM5-infected mice (P ⫽ 0.003 for ConA
and P ⫽ 0.02 for LPS). Collectively, these data demonstrate that CD8 ⫹ T cells are required for resistance to
LP-BM5 virus-induced MAIDS, consistent with a direct
role for BALB/cByJ-derived, gag-/SYNTGRFPPL-specific
CTLs in the resistant phenotype.

Identification of the peptide epitope recognized by
gag-specific CTLs derived from the CBY6F 1 and
C57BL/Ks mouse strains
To test the possibility that the CBY6F 1 strain recognized the same gag-associated CTL specificity as the
MAIDS-resistant BALB/c strain, a series of experiments
were carried out using, as a source of antigen, defective
or ecotropic gag-expressing Sindbis and vaccinia virus
recombinants and the synthetic, ORF2-derived peptide
that represents the minimal immunodominant epitope
identified in BALB/c mice. As shown in the representative experiment of Table 1, CBY6F 1 mice primed and
restimulated with dG-Vac, expressing AA 1–532 of the
defective gag protein (def-gag), efficiently lysed P815B
target cells either infected with a Sindbis virus expressing either def-gag AA 208–240 or AA 1–342, or pulsed
with the ORF2-derived SYNTGRFPPL peptide (61%, 60%,
and 58% specific lysis at an effector-to-target (E/T) ratio
of 100:1, respectively) compared with target cells infected
with a recombinant Sindbis virus expressing def-gag AA
208–225 or noninfected/untreated P815B (mock) target
cells (10% or ⫺1% specific lysis, respectively). Because
of the uniform activity against targets capable of expressing the ORF2-defined CTL epitope, including synthetic peptide pulsed P815B target cells, but not target
cells infected with SIN:dG(208–225), which does not encode the ORF2 epitope, these results were consistent
with SYNTGRFPPL as the major specificity of the F 1
anti-gag CTL. Similar to dG-Vac in vitro restimulation,
spleen cells from these same dG-Vac primed but not
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TABLE 1
CBY6F 1 Mice Generate Anti-Gag CTLs with Specificity for the ORF2-Derived SYNTGRFPPL Epitope a
Effector cell stimulation
Primary
in vivo
dG-Vac

Secondary
in vitro
dG-Vac c
K d-Vac c
None
SIN:dG(208–225)
J774.2 cells
SIN:dG(208–240)
J774.2 cells
SIN:dG(1–342)
J774.2 cells

Target cell % specific lysis for P815B cells
E/T
ratio

Mock

SIN:dG(208–225) b

SIN:dG(208–240) b

SIN:dG(1–342) b

ORF2
SYNTGRFPPL

100:1
20:1
100:1
20:1
100:1

⫺1
⫺3
⫺1
⫺3
0

10
5
38
20
⫺6

61
34
19
7
5

60
31
17
8
4

58
38
ND d
ND
4

100:1

1

22

19

17

19

100:1
20:1

1
⫺1

18
10

69
34

63
34

67
26

100:1
20:1

⫺1
⫺2

9
5

32
10

32
11

42
15

a 51
Cr release assay of CTLs, generated by priming CBY6F 1 mice i.p. with dG-Vac virus (2 ⫻ 10 7 pfu) followed by in vitro restimulation of primed
spleen cells with J774.A2 tumor cells infected with various recombinant Sindbis or vaccinia viruses, as indicated. P815 target cells were similarly
infected or pulsed with 100 pg/ml synthetic (ORF2) peptide epitope. Spontaneous release values for target cells were 16% or lower.
b
SIN:dG(208–240) and SIN:dG(1–342), versus SIN:dG(208–225) are Sindbis virus constructs encoding regions of the defective gag protein that do
versus do not encode for the ORF2-derived SYNTGRFPPL epitope.
c
dG-Vac is a recombinant vaccinia virus construct encoding for the entire defective gag protein, whereas K d-Vac is a control that encodes for the
d
K MHC class I protein.
d
ND, not determined.

nonimmunized CBY6F 1 mice (data not shown) were successfully restimulated with recombinant Sindbis viruses
expressing def-gag AA 208–240 or 1–342 but not 208–
225. These CTLs caused substantial lysis above background of the same set of ORF2 epitope-encoding recombinant Sindbis virus-infected P815B target cells and
those target cells pulsed with SYNTGRFPPL peptide (Table 1). Reverse transcription–polymerase chain reaction
(RT–PCR) demonstrated that all minigene RNA products
were expressed in the Sindbis-infected target cells used
in this experiment, and maintenance of an ORF was
confirmed by sequencing of the viral plasmids (data not
shown). Collectively, these results regarding anti-gag
CTL fine specificity confirmed in two additional experiments using dG-Vac in vivo priming were consistent with
the hypothesis that the SYNTGRFPPL peptide acts as the
immunodominant CTL epitope in F 1 mice.
A CBY6F 1 CTL specificity for SYNTGRFPPL was further
supported by experiments demonstrating that CTLs were
also generated from mice primed with eG-Vac, but not
naive mice, after restimulation of primed spleen cells in
vitro with ORF2-derived SYNTGRFPPL peptide. These
CTLs efficiently lysed P815B target cells either infected
with SIN:dG(208–240) or pulsed with the SYNTGRFPPL
peptide compared with little or no lysis of mock infected
target cells or those infected with SIN:dG(208–225) (Fig.
2). RT–PCR was again used to verify expression of all
recombinant Sindbis-encoded minigene RNA products in
these P815B target cells (data not shown). The lack of

lysis of NK-susceptible Yac-1 target cells underscored
the specificity of the response. Two repeat experiments
employing eG-Vac priming demonstrated similar results
as those depicted in Fig. 2, suggesting that like the
BALB/c strain, the CBY6F 1 mice recognized the ORF2derived SYNTGRFPPL epitope of either def- or eco-gag
origin.
To evaluate the in vivo immunogenicity of ORF2-derived SYNTGRFPPL epitope under conditions where its
expression was not driven by a recombinant virus expression system (i.e., Sindbis or vaccinia virus), CBY6F 1
mice were primed by infection with the LP-BM5 retroviral
complex and evaluated for their ability to generate secondary anti-gag, and specifically anti-SYNTGRFPPL, CTL
responses. LP-BM5 primed spleen cells restimulated
with the SYNTGRFPPL peptide efficiently lysed target
cells infected with either SIN:dG(208–240) or SIN:dG(1–
342) (69% or 82% specific lysis, respectively) compared
with mock or SIN:dG(208–225)-infected targets (24% or
20% specific lysis, respectively) at a 100:1 E/T ratio (Table
2). These data provided additional evidence that SYNTGRFPPL is the immunodominant peptide recognized by
CBY6F 1-derived gag-specific CTL. RT–PCR was again
used to verify expression of all minigene messages in
the Sindbis-infected P815B target cells, and maintenance
of the insert ORFs was confirmed by sequencing the viral
construct (data not shown). These results demonstrated
that similar to recombinant Sindbis- or vaccinia vectormediated expression, in vivo LP-BM5 retrovirus infection
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FIG. 2. Recognition of the ORF2-derived SYNTGRFPPL by gag-specific CTLs generated in the CBY6F 1 strain. Gag-specific CTLs were generated
by eG-Vac priming CBY6F 1 mice, followed by in vitro restimulation with synthetic, ORF2-derived SYNTGRFPPL peptide. Lytic activity was measured
using 51Cr-radiolabeled target cells: P815B, either infected with the indicated def-gag-expressing Sindbis recombinants (see Table 1) or pulsed with
100 pg/ml ORF2-derived SYNTGRFPPL peptide, or Yac-1, as a target cell highly susceptible to lysis by NK cells. Percent specific lysis at an E/T ratio
of 100:1 is shown, although other E/T ratios were used with a similar pattern of results. Spontaneous release values for target cells were 28% or lower.

leads to the physiological production of immunogenic
levels of the SYNTGRFPPL peptide sufficient to prime
SYNTGRFPPL-specific precursor CTLs in CBY6F 1 mice,
as we had previously shown in MAIDS-resistant BALB/c
mice (Mayrand et al., 1998). Similar results were obtained in two repeat experiments. Collectively, these data
confirmed that gag-specific CTLs derived from CBY6F 1
mice recognize the same ORF2-derived SYNTGRFPPL
peptide as the MAIDS-resistant BALB/c strain.
Because, as mentioned earlier, a population of gagspecific CTLs derived from the MAIDS-resistant
C57BL/Ks mouse strain also recognizes a K d-presented
epitope located within the gag protein of the defective
virus, a similar series of experiments were performed to
determine the CTL fine specificity of this strain. Similar to
BALB/c (Mayrand et al., 1998) and CBY6F 1 (Table 2) mice,

LP-BM5 primed and SYNTGRFPPL peptide or SIN:
dG(208–240) restimulated C57BL/Ks effector cells demonstrated substantial lysis (above background levels) of
only those P815B target cells infected with recombinant
Sindbis viruses expressing the ORF2-SYNTGRFPPL
epitope, not mock or SIN:dG(208–225)-infected target
cells or NK-susceptible Yac-1 targets (data not shown).
These findings were supported by data from both a
repeat LP-BM5 priming experiment in which a similar
pattern of results was obtained, although the lysis values
were somewhat lower, and three experiments in which
anti-ORF2/SYNTGRFPPL C57BL/Ks CTLs were produced
after appropriate in vitro restimulation of dG-Vac primed
mice. Taken together, these results strongly suggested
that the gag-specific CTLs derived from MAIDS-resistant
C57BL/Ks mice recognize the same ORF2-generated

TABLE 2
CBY6F 1 Mice Primed with LP-BM5 Virus Generate Anti-Gag CTLs with Specificity for the ORF2-Derived SYNTGRFPPL Epitope a
Effector cell stimulation
Primary in vivo
LP-BM5 virus

Secondary in vitro
None
ORF2-SYNTGRFPPL

Target cell % specific lysis for P815B cells
E/T
ratio

Mock

SIN:dG(208–225)

SIN:dG(208–240)

SIN:dG(1–342)

Yac-1 b

100:1
20:1
100:1
20:1

30
18
24
16

14
12
20
11

31
21
69
51

32
30
82
61

9
3
7
4

a
CTLs were generated by priming CBY6F 1 mice i.p. with LP-BM5 virus (1.8 ⫻ 10 5 pfu, followed by in vitro restimulation of primed spleen cells with
10 g/ml synthetic ORF2 peptide epitope as indicated. Spontaneous release values for 51Cr-labeled target cells, including those infected with various
recombinant Sindbis viruses, as described in Table 1, were 11% or lower.
b
Yac-1 is a target cell highly susceptible to lysis by NK cells.
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FIG. 3. Determination of the MAIDS phenotype of CBY6F 1 mouse via spleen hyperplasia. Adult (5 weeks old) CBY6F 1 or C57BL/6 mice were infected
i.p. with LP-BM5 virus (1.8 ⫻ 10 5 pfu). At 15 weeks post-virus delivery, spleen weight was determined as a measurement of MAIDS susceptibility or
resistance. All mice (n ⫽ 30) were age matched at the time of LP-BM5 delivery. Data depicted represents the group mean ⫾ SD. Student’s t
test-determined P values ⬍0.05 were accepted as statistically significant differences among treatment groups.

SYNTGRFPPL peptide as those derived from the BALB/c
and CBY6F 1 strains.
Characterization of the MAIDS phenotype of the
CBY6F 1 mouse strain
As discussed, according to the published literature
(Makino et al., 1990; Huang et al., 1992), susceptibility to
MAIDS, rather than resistance, is dominant, at least in
the F 1 strains used in those studies. Although the CBY6F 1
strain might thus be expected to also be susceptible to
LP-BM5-induced MAIDS, it seemed curious to us that
only two of the three H-2 d-positive mice strains that were
shown to be capable of generating gag-specific/antiSYNTGRFPPL responses would be resistant to MAIDS.
To directly address the issue of MAIDS resistance versus susceptibility, the disease phenotype of the CBY6F 1
strain was assessed via intraperitoneal delivery of LPBM5 virus to adult mice, followed by standard measurements of the hallmark MAIDS features: splenomegaly
and hypergammaglobulinemia. As depicted in Fig. 3,
when uninfected versus LP-BM5 virus-infected CBY6F 1
mice were compared, no significant differences were
observed (P ⫽ 0.27) with respect to spleen weight at 15
weeks postinfection. By contrast and as expected, susceptible C57BL/6 mice infected with LP-BM5 had significant splenomegaly compared with noninfected C57BL/6
mice (P ⫽ 0.005). Additionally, visual observation of the
lymph node sizes indicated no LP-BM5-induced enlargement in the CBY6F 1 mice, whereas massive enlargement
of lymph nodes was observed in infected C57BL/6 mice.
These data suggested that there was no LP-BM5 virus-

induced hyperplasia of lymphoid organs in CBY6F 1 mice
at a time when B6 mice were found to be MAIDS susceptible.
As an independent measurement of MAIDS induction,
serum Ig levels were determined at 6 and 15 weeks after
LP-BM5 delivery. As reported in the literature, the serum
Ig levels in highly susceptible C57BL/6 mice achieved
maximal plateau levels at 4–8 weeks after LP-BM5 infection (Pattengale et al., 1982). Hence, the 6-week serum
samples are shown to demonstrate that although the
LP-BM5-infected C57BL/6 mice had serum IgG 2a and
IgM levels significantly higher (P ⫽ 0.01 and 0.001, respectively) than noninfected C57BL/6 mice, no significant differences were detected between LP-BM5-infected and naive CBY6F 1 mice (IgG 2a, P ⫽ 0.28; IgM, P ⫽
0.47; Figs. 4A and 4B, respectively). With disease progression, the serum Ig levels in MAIDS mice began to
decline, most likely as a result of the functional inactivation of the B cells as immunodeficiency develops. As a
result, the elevation in serum Ig levels from the 15-week
postvirus serum samples was less pronounced in the
LP-BM5-infected C57BL/6 mice but still highly significant
(IgG 2a, P ⫽ 0.01; IgM, P ⫽ 0.003; data not shown). In
contrast, because as late as 15 weeks after LP-BM5 virus
infection, CBY6F 1 mice had serum IgG 2a (P ⫽ 0.30) and
IgM (P ⫽ 0.42) levels comparable to naive mice, we
concluded that LP-BM5 infection of adult CBY6F 1 mice
does not cause hypergammaglobulinemia.
Results from an additional independent experiment
using the same F 1 strain (n ⫽ 15) confirmed the lack of
elevation of serum Ig levels in CBY6F 1 mice infected with
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FIG. 4. Determination of the MAIDS phenotype of CBY6F 1 mouse via serum Ig levels after LP-BM5 infection. Adult (5 weeks old) CBY6F 1 or C57BL/6
mice were infected i.p. with LP-BM5 virus (1.8 ⫻ 10 5 pfu). At 6 weeks post-virus delivery, mice were bled and an ELISA was used to determine the
relative levels of serum IgG 2a (A) and IgM (B). All mice (n ⫽ 30) were age matched at the time of LP-BM5 delivery. Data depicted represent the group
mean ⫾ SD. Student’s t test-determined P values ⬍0.05 were accepted as statistically significant differences among treatment groups.

the LP-BM5 virus (data not shown). Because measurements of spleen hyperplasia and hypergammaglobulinemia are routinely used as prototypical disease features
to determine MAIDS susceptibility or resistance (Pattengale et al., 1982), these data demonstrating both a lack of
splenomegaly and normal serum Ig levels as late as 15
weeks postvirus suggested that contrary to other F 1
strains that have been reported on (Makino et al., 1990,
1991; Huang et al., 1992), resistance is dominant over
susceptibility in CBY6F 1 mice.
These results, which are considered in light of our
correlation between MAIDS resistance and the ability to

mount anti-ORF2/SYNTGRFPPL, gag-specific CTL responses in the context of H-2 d, but not H-2 b, further
implied that the primary genetic factor in determining
MAIDS resistance versus susceptibility might be the
codominant expression of the resistant H-2 d haplotype.
To extend the analysis of the induction of MAIDS in mice
expressing the H-2 b and/or H-2 d haplotypes, particularly
given the disparity of the findings for F 1 strains in the
literature versus our demonstration of the MAIDS-resistant phenotype of CBY6F 1 mice (Figs. 3 and 4), additional
experiments were conducted using F 2 mice obtained
from the intercrossing of CBY6F 1 mice. The resulting F 2
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FIG. 5. The absence of splenomegaly and hyper-Ig levels after LP-BM5 injection correlates with the presence of the H-2 d allele, indicating protection
from MAIDS was conferred by H-2 d. CBY6F 1 (H-2 d⫻b) were crossed to generate H-2 b/b, H-2 d/d, and H-2 d/b intercross progeny. These F 2 mice were
genotyped and then infected with 0.5 ml of LP-BM5 mixture at 6 weeks of age. Mice were serially bled at 3- to 4-week intervals, and total Ig levels
were determined by ELISA. At the time of sacrifice (when mice were moribund or at 27 weeks), all mice were tested for the presence of defective
gag by PCR. Spleen size and/or spleen cells counts were determined, and a numerical score of 1, 2, or 3 was assigned (see Materials and Methods).
Data are plotted as the spleen size versus highest Ig level at any point during the study, and the mean values are indicated for all data groups. E,
Defective gag-negative mice. F, Defective gag-positive mice. H-2 b/b mice were all positive for defective virus (47 mice), whereas H-2 d/d mice were
found to be virus positive (15 mice) and negative (33 mice), and H-2 b/d mice were found to be both virus positive (32 mice) and negative (52 mice).
Values directly above data points refer to the numbers of mice in each group. For reference, bars are present at the highest Ig levels for virus-negative
H-2 d/d mice and H-2 b/d mice; the Ig values for virus-negative H-2 b/d mice are used as the uninfected Ig value for H-2 b/b mice.

mice should allow independent segregation of non H-2
genetic traits possibly influencing the development of
MAIDS from the proposed “resistant” (H-2 d/d and H-2 b/d)
and “susceptible” (H-2 b/b) H-2 genotypes. When H-2 d/d or
H-2 b/d mice were compared with H-2 b/b F 2 mice with
respect to serum Ig levels at various time points after
infection with the LP-BM5 virus, both H-2 d/d and H-2 b/d F 2
mice demonstrated roughly comparable serum Ig levels,
substantially lower than those of the H-2 b/b F 2 mice,
which had strongly elevated levels during the 3- to 12week postinfection period (data not shown). This lack of
obvious hypergammaglobulinemia was observed for
both H-2 d/d and H-2 b/d F 2 mice and was essentially independent of whether the mice were scored as LP-BM5
defective virus positive or negative by PCR assessment
of viral DNA. The defective virus-positive F 2 mice of the
H-2 d/d genotype, which is associated with MAIDS resistance (Makino et al., 1990), had somewhat higher levels
of Ig at the 10- to 16-week time period than the defective
virus-positive F 2 H-2 b/d mice. However, this elevation in Ig
levels in defective virus-positive H-2 d/d mice was transient, in that it was not sustained at time points extending out to 24 weeks postinfection. By contrast, all H-2 b/b
F 2 mice were defective virus positive and presented with
hyper-Ig (data not shown), similar to that previously demonstrated for the LP-BM5 infected, prototypic MAIDSsusceptible B6 mice.
Further analysis of these same LP-BM5 virus-injected
F 2 mice is depicted in Fig. 5. F 2 mice are grouped on the

basis of their highest serum Ig levels, MHC genotype,
spleen weights, and defective virus status. When all mice
were analyzed in this manner, several distinct differences emerged. First, with respect to serum Ig levels
after infection with the LP-BM5 virus, most H-2 d/d (77%)
and H-2 b/d F 2 (81%) mice demonstrated “normal” serum Ig
levels relative to the significantly elevated serum Ig levels of H-2 b/b F 2 mice. Specifically, 91% of H-2 b/b F 2 mice
had serum Ig levels greater than 5953 g/ml, which is
the highest value of defective virus-negative H-2 b/d mice
(Fig. 5). Second, although only 23% of H-2 d/d and 19% of
H-2 b/d F 2 mice demonstrated at least one aspect of disease (spleen hyperplasia and/or elevated Ig levels),
100% of H-2 b/b F 2 mice displayed at least one aspect of
disease (Fig. 5). Third, these results demonstrate that the
development of MAIDS in the “resistant” H-2 d/d F 2 mice
was similar to that in H-2 b/d F 2 mice. Thus we found that
H-2 b/d mice, whether they be F 1 or F 2 intercrosses, presented with a MAIDS-resistant phenotype.
DISCUSSION
Our finding that CBY6F 1 (H-2 d⫻b) and both H-2 d/d and
H-2 b/d F 2 mice possess a MAIDS-resistant phenotype,
compared with H-2 b/b F 2 mice, was of particular interest
in view of the studies by Makino et al. (1990) and Huang
et al. (1992), which both concluded that susceptibility,
rather than resistance, is dominant in F 1 (resistant ⫻
susceptible or susceptible ⫻ resistant) mice. Makino et

446

MAYRAND ET AL.

al. (1990) used F 1 hybrids of the MAIDS-susceptible,
(C57BL/6 or C57BL/10) strain crossed with a highly resistant (B10.D2 or A/J) or moderately resistant (B10.BR or
B10.A) strain in the evaluation of the dominance of susceptibility versus resistance to LP-BM5 virus-induced
MAIDS. Although limited by the number of animals evaluated, this study concluded that all F 1 strains examined
demonstrated some signs of MAIDS (i.e., splenomegaly
and histopathology) by 10 weeks postinfection. Interestingly, most F 1 strains examined by Makino et al. (1990)
demonstrated a significantly delayed onset of disease.
Although disease onset occurred at 3–4 weeks in prototypic, MAIDS-susceptible C57BL/6 mice, MAIDS onset
was not clearly identified until 10–15 weeks postinfection
in the F 1 mice (Makino et al., 1990). In keeping with the
notion of F 1 MAIDS susceptibility but with kinetics similar
to those of B6 mice, Huang et al. (1992) demonstrated
MAIDS onset as early as 4–5 weeks in F 1 progeny of
susceptible C57BL/6N females crossed with males from
the resistant LG/J strain. Taken together, the data from
these two studies suggested that although disease onset may be delayed in some F 1 strains, MAIDS susceptibility appears to be dominant over resistance.
In direct contrast to these findings, we report here that
no symptoms of MAIDS onset were observed in CBY6F 1
(H-2 d⫻b) mice, whereas 77% of H-2 d/d and 81% of H-2 b/d F 2
mice did not exhibit MAIDS after LP-BM5 infection.
These data are consistent with a study by HammelinBourassa et al. (1989) that demonstrated F 1 progeny of
the susceptible C57BL/6 ⫻ resistant A/J strains were
more resistant than susceptible to LP-BM5 virus-induced
MAIDS. Additionally, Makino et al. (1991) reported that
only 45% of the F 1 progeny of the resistant RIIIS ⫻
susceptible B10.RIII strains were MAIDS susceptible.
Given the apparent strain dependence of the dominance
of resistance or susceptibility to MAIDS of F 1 mice and
the disparate findings reported by various laboratories, a
more complete analysis of the inheritance of genes controlling MAIDS resistance versus susceptibility in F 1 and
F 2 mice may help to explain the reported differences.
Indeed, Makino et al. (1990) demonstrated that non-MHC
background genes influenced the development of
MAIDS. We also find a small subset of resistant H-2 d/d F 2
mice somewhat susceptible to MAIDS, consistent with
the interpretation that non-H-2 genes influenced the development of MAIDS.
Our finding that CBY6 F 1 mice generate anti-gag-specific CTLs with a fine specificity shared by the MAIDSresistant BALB/c and C57BL/Ks strains (Table 1, Fig. 2)
supports the argument that (resistant ⫻ susceptible) F 1
mice that are capable of responding to defective gag are
resistant to LP-BM5-induced MAIDS. The results described in this report should also be considered in light
of our previous correlation between MAIDS resistance
and the ability to mount such anti-ORF2/SYNTGRFPPL,
gag-specific CTL responses in the context of H-2 d, but

not H-2 b (Schwarz and Green, 1994; Mayrand et al., 1998;
Mayrand and Green, 1998). Taken together, our studies
suggest that a primary factor in the determination of
MAIDS resistance versus susceptibility most likely is the
codominant expression of the resistant H-2 d haplotype,
which allows for K d-restricted CD8 ⫹ CTL production. Indeed, our experiments, in which chronic in vivo depletion
of CD8 ⫹ T cells in genetically resistant mice caused
them to become MAIDS susceptible (Fig. 1), provide
direct linkage of the ability to raise anti-gag CTLs with
resistance. These findings are in agreement with the
results of Makino et al. (1992), which demonstrated that
resistant A/J mice were rendered susceptible to MAIDS
after in vivo depletion of the CD8 ⫹ T-cell population.
Interestingly, however, 19% of H-2 d/b and 23% of the resistant H-2 d/d F 2 mice had at least one clinical aspect of
MAIDS, suggesting that a non-MHC genetic determinant
can negatively influence T-cell protection and thus disease outcome.
MATERIALS AND METHODS
Mice
BALB/cByJ (H-2 d), C57BL/KsJ (H-2 d), C57BL/6J (H-2 b),
and CBY6F 1 (H-2 d⫻b) mice (4 weeks old) were obtained
from The Jackson Laboratories (Bar Harbor, ME). Additional CBY6F 1 (H-2 d⫻b) mice were produced by breeding
BALB/cByJ and C57BL/6J mice at the animal facility of
The Scripps Research Institute. CBY6F 2 H-2 b/b, H-2 d/d, and
H-2 d/b mice were generated by inter-cross-breeding of
the CBY6F 1 (H-2 d⫻b) mice at the animal facility of The
Scripps Research Institute. At 4 weeks of age, mice were
MHC typed by a PCR-based assay (see later).
CD8 ⫹ T-cell depletion in vivo
To test the effect of depletion of CD8 ⫹ T cells in a
MAIDS-resistant mouse strain, prototypic MAIDS-resistant, adult BALB/cByJ mice were injected i.p. with 0.25 ml
(⬃0.25 g) purified ascites fluid containing the murine
CD8-specific mAb 53-6.72 (IgG 2a rat anti-mouse, TIB 105;
American Type Culture Collection, Rockville, MD.) on day
7 after LP-BM5 virus infection. Identical weekly injections
of anti-CD8-containing ascites were delivered i.p. (up to
2 weeks before sacrifice) to maintain depletion throughout the course of the experiment. Flow cytometric analysis was performed periodically on splenocytes derived
from control mice that received the same regimen of
anti-CD8 mAb to confirm efficient chronic depletion of
CD8 ⫹ T cells (i.e., ⬎95% reduction in percent CD8 ⫹
cells).
Medium
In addition to L-glutamine (2 mM), penicillin (30 g/ml),
streptomycin (20 mg/ml), and gentamicin (33 g/ml), medium contained the following additional components:
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RPMI-10 (RPMI 1640 and 10% FBS), RPMI-10ME
(RPMI-10 plus 50 mM 2-mercaptoethanol), DMEM-10
(Dulbecco’s modified Eagle’s medium, 10 mM HEPES,
and 10% FBS), sensitization media (SM: RPMI-10ME plus
0.1 M nonessential amino acids, 1 mM sodium pyruvate),
and SM-rIL2 (SM plus 8 units/ml recombinant interleukin-2). RPMI 1640 containing 10% calf serum was used
for conducting 51Cr release assays.
Cell lines
The murine lines J774.2 (macrophage, H-2 d; American
Type Culture Collection) passaged in DMEM-10, P815B
(mastocytoma, H-2 d, a generous gift from Dr. Jack Bennink, National Institutes of Health, National Institute of
Allergy and Infectious Diseases, Bethesda, MD) passaged in RPMI-10ME, and Yac-1 (Moloney murine leukemia virus-induced tumor, H-2 a) passaged in RPMI-10
were used in this series of experiments.
LP-BM5 virus
LP-BM5 virus was prepared in our laboratory as described by Klinken et al. (1988). G6 cells, originally provided to us by Drs. Jane Hartley and Herbert Morse as a
cloned cell line from SC-1 cells infected with the LP-BM5
virus mixture, were cocultured with noninfected SC-1
cells and cell-free supernatants were harvested, Millipore filtered, and titered. Mice were infected intraperitoneally with 0.25 ml of virus stock that was quantified by
an XC plaque assay (Rowe et al., 1970) to contain approximately 7 ⫻ 10 5 ecotropic plaque-forming units
(pfu)/ml.
Recombinant viruses
K d-Vac, a recombinant vaccinia virus encoding the
H-2K d class I molecule, was a generous gift from Dr. Jack
Bennink. Additional recombinant vaccinia and Sindbis
viruses were generated using established protocols
(Earl and Moss, 1993; Hahn et al., 1992). Intermediate
shuttle vectors, used to create the indicated recombinant
viruses described later, were constructed using established procedures (Sambrook et al., 1989) or manufacturer-specified protocols. The pSC65 shuttle vector and
the Western Reserve isolate of vaccinia virus were generously provided by Dr. Bernard Moss (National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD). The vectors for recombinant Sindbis virus generation, pH3⬘2J1 (shuttle vector)
and pTE3⬘2J:CAT, were generously provided by Dr.
Chang Hahn (University of Virginia, Charlottesville, VA).
Plasmid maps will be provided on request. The construction of the recombinant vaccinia and Sindbis viruses
expressing ecotropic gag (eG), defective gag (dG), or
portions of dG have previously been published (Schwarz
and Green, 1994; Mayrand et al., 1998). Briefly, for vaccinia, inserts were cloned into the shuttle vector pSC65,

447

and the following recombinant viruses were generated
via homologous recombination between pSC65 and the
Western Reserve isolate of vaccinia virus: dG-Vac, containing the entire def-gag sequence (AA 1–532 of the
p1/27/A1 retrovirus clone), and eG-Vac, containing the
entire ecotropic gag sequence (AA 1–536 of the pEco12
retrovirus clone), which were the generous gifts of Dr.
Sisir Chattopadhyay, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD (Chattopadhyay et al., 1991). The construction of recombinant Sindbis viruses has also been described in detail (Schwarz and Green, 1994; Mayrand et
al., 1998). Briefly, inserts were cloned into the shuttle
vector pH3⬘2J1, a fragment containing the insert and
subgenomic promoter was subcloned into the full-length
Sindbis cDNA contained in pTE3⬘2J:CAT, and infectious
Sindbis virus was recovered after LipoFECTIN (GIBCO
BRL, Grand Island, NY)-mediated transfection of viral
RNA into BHK-21 (cl.13) cells to create the recombinant
viruses encoding the following portions of dG AA 1–532:
SIN:dG (1–342), SIN:dG (208–240), and SIN:dG (208–225).
Infection of stimulator and target cells
Next 1 ⫻ 10 7 (vaccinia virus) or 5 ⫻ 10 7 (Sindbis virus)
pfu was added to 1 ⫻ 10 6 P815B or J774.2 cells in 500 ml
of a balanced salt solution containing 0.1% BSA and
allowed to adsorb for 1 h at 37°C with agitation. For
vaccinia target cells, samples were incubated at 37°C for
an additional 3 h. before 51Cr labeling. Sindbis targets
were infected in the same manner but were allowed to
express viral proteins for a minimum of 6 h before 51Cr
labeling. Under these infection conditions, including this
50:1 m.o.i. for Sindbis virus, essentially 100% of target
and stimulator cells infected by the recombinant viruses
have previously been shown by flow cytometry and other
techniques to express the inserted retroviral protein sequence (Schwarz and Green, 1994; unpublished observations).
Synthetic peptides
The ORF2 peptide (SYNTGRFPPL) was synthesized
with unmodified NH 2- and COOH-terminal amino acids
using fluorenylmethoxycarbonyl (FMOC)-based chemistry by Research Genetics (Huntsville, AL).
Generation of bulk cytolytic effector cells
Six to 10-week-old mice were infected intravenously
with 1–2 ⫻ 10 7 pfu dG-Vac, 2 ⫻ 10 7 pfu eG-Vac, or 1.8 ⫻
10 5 pfu LP-BM5 virus. At least 3 weeks postinfection for
recombinant vaccinia priming or 7–10 days for LP-BM5
priming, primed mice were sacrificed and splenic leukocytes were recovered. As a source of stimulatory antigen, 1 ⫻ 10 6 P815B or J774.2 cells were irradiated (8000
rads), infected with the appropriate recombinant virus,
and added to 4 ⫻ 10 7 to 5 ⫻ 10 7 primed leukocytes in
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MLTC cocultures. Vaccinia virus-specific effectors were
generated by directly adding vaccinia virus (dG-Vac or
K d-Vac) to responder cells at an m.o.i. of 10:1. Peptide
stimulation was achieved by the addition at a final concentration of 10 g/ml. Our previous studies have shown
that even for recombinant vaccinia virus-mediated in vivo
priming of resistant mice, both in vivo priming and in vitro
restimulation with sources of retroviral epitopes are necessary for easy detection of antiviral CTL activity in both
the MAIDS and other murine retroviral systems (Schwarz
and Green, 1994; unpublished observations). Cells were
cultured in MLTC in RPMI-10 for 6 days at 37°C in a
humidified 5% CO 2 atmosphere.
Chromium release assay
Target cells (10 6 to 2 ⫻ 10 6) were resuspended in 100
l of FBS and labeled with 200 Ci of 51Cr sodium
chromate (New England Nuclear, Wilmington, DE) for 45
min at 37°C. After washing, 4 ⫻ 10 3 or 10 4 target cells
were combined with serial dilutions of effector cells in
96-well V-bottom plates. After a 4-h incubation at 37°C,
100 l of cell-free supernatant was collected and
counted. Percent specific lysis of tumor cells was determined using the formula [(a ⫺ b)/c] ⫻ 100, where a is
experimental counts per minute released by target cells
incubated with effector cells, b is counts per minute
released by target cells incubated alone (spontaneous
release), and c is counts per minute released by the
freeze-thaw of target cells (approximately 80% of total
counts per minute incorporated), and ⬍10% variation
was seen between experimental replicates.
RT–PCR
Total RNA was recovered from target cells using a
CsTFA-based kit from Pharmacia (Piscataway, NJ) and
standard procedures previously described (Schwarz and
Green, 1994; Mayrand et al., 1998). After ethanol precipitation, each cDNA sample was subjected to 30 cycles of
Taq polymerase amplification consisting of 45 s denaturation at 94°C, 60 s annealing at 50°C, and 90 s chain
elongation at 72°C with the following primers: pH3⬘-59,
5⬘-GGAAATAAAGCATCTCTACG-3⬘, and pH3⬘⫹65, 5⬘CTAATGTACCAGCCTGATGC-3⬘.
MHC genotyping
F 2 mice produced by CBY6F 1 (H-2 d⫻b) inter-crossbreeding were typed for their MHC by microsatellite
analysis (Dietrich et al., 1992) using a rapid DNA screening protocol developed by Chen and Evans (1993). Tissue was obtained from the ear or the last 0.5 mm of the
tail of 4- to 5-week-old mice and digested using Proteinase K digestion, and the DNA was prepared for PCR
amplification as described by Chen and Evans (1993).
The DNA samples were amplified with primers to
D17Mit28 (MAPPAIRS, Research Genetics, Inc., Hunts-

ville, AL), which allows the MHC haplotype determination
of mice as H-2 d, H-2 b, and H-2 d⫻b through the detection of
known microsatellites (see Dietrich et al., 1992 and http://
www.informatics.jax.org/searches/marker_form.shtml).
PCRs were in 25-l volumes using standard reagents
(Perkin–Elmer Cetus, Norwalk, CT) with concentrations
of 1.5 mM MgCl 2 and primers to 0.4 M. Reactions were
carried out for 35 cycles at 94°C for 30 s, 55°C for 30 s,
and 72°C for 1 min. All PCR analyses included reagent
only reactions to control for false-positives. The PCR
products, 10 l, were run out on 6% acrylamide gels, and
the bands were visualized with ethidium bromide staining. PCR product from the amplification of DNA from the
isolated from the tissues of H-2 d, H-2 b, and H-2 d⫻b mice
were run on each gel to serve as a positive size control
for distinguishing bands from the PCR product of DNA
obtained from the mice to be typed.
Detection of defective gag viral genomes
F 2 mice injected with LP-BM5 virus were evaluated
for MAIDS by both clinical (as above) and molecular
means. To determine the presence of integrated defective virus. DNA samples were obtained from the
spleen and lymph nodes of mice (as described earlier)
and assessed for the presence of the p12 region of
defective virus by PCR analysis. Primers to the defective p12 region were as described (Ogata et al., 1993).
All samples included DNA from noninfected mice and
mice infected with pEco12, a cloned ecotropic murine
leukemia virus (kindly provided by Dr. S. Chattopadhyay, Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases), and known
MAIDS positive mice as controls. PCRs were in 25-l
volumes using standard reagents (Perkin–Elmer Cetus) with concentrations of 1.5 mM MgCl 2 and primers
to 0.5 M. Reactions were carried out for 35 cycles at
94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. PCR
products were detected as described above.
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